Cresco Labs Delivers Q4 2025 Revenue of $162 Million and Sequential Margin Improvement
MWN-AI** Summary
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) has reported its financial results for the fourth quarter and the fiscal year ended December 31, 2025, showcasing impressive revenue and margin growth. The company generated Q4 revenue of $162 million and a total of $656 million for the fiscal year, marking a solid performance despite industry challenges.
Notably, gross profit for the quarter reached $83 million, with an adjusted gross margin of 52.2%, a significant increase from the previous quarter. This reflects the company's focus on improving operational efficiencies and enhancing profitability. Adjusted EBITDA for Q4 was $40 million, yielding a robust adjusted EBITDA margin of 25.0%. In this period, Cresco Labs also recorded operating cash flow of $27 million, contributing to a respectable $73 million in operating cash flow for the entire fiscal year.
However, the company reported a net loss of $89 million for Q4, driven by one-time, non-cash charges including a $93 million impairment charge related to its New York reporting unit, amidst a backdrop of industry consolidation. Notably, Cresco Labs successfully retained its leading market share in various key markets throughout the year.
Management emphasized a commitment to building a cash-generating platform while balancing organic growth with strategic acquisitions. They aim to capitalize on ongoing consolidation within the cannabis sector and the potential for federal reform to create long-term shareholder value. With a focus on strengthening its competitive position through brand leadership and retail execution, Cresco Labs remains positioned for sustainable growth.
The company’s detailed financial results, including specific adjustments, are forthcoming as they prepare for the completion of their annual audit, expected to be finalized by March 5, 2026.
MWN-AI** Analysis
Cresco Labs (CSE: CL) (OTCQX: CRLBF) recently reported solid financial results for Q4 2025, achieving revenues of $162 million along with a notable sequential improvement in gross margin to 52.2%. The company’s performance underscores its dominant position in the cannabis sector, particularly in lucrative markets, and its commitment to strategic growth while navigating the competitive landscape.
Despite a net loss of $89 million attributed to significant non-cash charges, Cresco's adjusted EBITDA margins improved to 25%. This indicates a robust operational foundation amid industry headwinds. The firm displayed prudent management of selling, general, and administrative expenses, achieving a year-over-year reduction in adjusted SG&A by 5.7% to $200 million.
Following these results, potential investors might view Cresco Labs as a strong candidate for consideration in portfolio allocations. The company’s ability to enhance profitability while expanding brand share presents opportunities for long-term growth, particularly as cannabis markets mature and consolidate. Given the growing emphasis on cash flow generation — evidenced by a $27 million operating cash flow for Q4 — Cresco Labs is positioned well to capitalize on organic growth and selective acquisitions.
That said, investors should remain cautious due to the inherent volatility in the cannabis industry, heavily influenced by regulatory changes and market dynamics. With a significant portion of Cresco's reported losses tied to non-cash items, it’s essential to focus on operational performance metrics instead of net income alone. Overall, Cresco Labs appears to be navigating its expansion strategy effectively, aligning capital allocation and operational efficiencies to sustain its market leadership. As the industry evolves, maintaining close attention to Cresco’s progress and strategic shifts will be imperative for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“ Cresco Labs ” or the “ Company ”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the fourth quarter ended and year ended December 31, 2025. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company’s investor website, here .
Fiscal Year 2025 Highlights
- Revenue of $656 million. Operating cash flow of $73 million and Free Cash Flow 1 of $38 million.
- Gross profit of $325 million. Adjusted gross profit 1 of $329 million; and an Adjusted gross margin 1 of 50.2%.
- SG&A of $218 million. Reduced Adjusted SG&A 1 by 5.7% year-over-year to $200 million, or 30.4%.
- Net loss of $140 million, which includes one-time, non-cash charges of $105 million related to the Company’s impairment of intangibles and goodwill associated with the write-down of the New York reporting unit and fair value adjustments to the California reporting unit related to the sale of Sonoma’s Finest.
- Adjusted EBITDA 1 of $157 million and Adjusted EBITDA margin 1 of 24.0%.
- Retained the No. 1 share position in multiple billion dollar markets for the full year. 2
Fourth Quarter 2025 Highlights
- Fourth quarter revenue of $162 million. Fourth quarter operating cash flow of $27 million.
- Gross profit of $83 million. Adjusted gross profit 1 of $84 million; and an Adjusted gross margin 1 of 52.2%.
- SG&A of $57 million or 35.3% of revenue.
- Net loss of $89 million, which includes one-time, non-cash charges of $93 million related to the write-down of the New York reporting unit.
- Fourth quarter Adjusted EBITDA 1 of $40 million and Adjusted EBITDA margin 1 of 25.0%.
- Retained the No. 1 share position in multiple billion dollar markets. 2
Management Commentary
“In Q4, we strengthened our financial foundation while expanding margins and generating meaningful cashflow. We delivered $162 million in revenue, $40 million in Adjusted EBITDA, and $27 million in operating cashflow, with sequential improvement across multiple profitability metrics. Our focused strategy continues to enhance our competitive position.”
“The cannabis industry is consolidating in real time, and Cresco Labs is operating from a position of strength – we continue to show that we win where we operate. We are intentionally building a productive cash-generating platform, balancing organic expansion with selective, accretive acquisitions while maintaining a strong balance sheet. With leading brand share, differentiated retail execution, and embedded operating leverage, Cresco Labs is positioned to capitalize on industry consolidation and federal reform to create long-term value for shareholders.”
1 See “Non-GAAP Financial Measures” at the end of this press release for more information regarding the Company’s use of non-GAAP financial measures.
2 According to Hoodie Analytics.
Balance Sheet, Liquidity, and Other Financial Information
- As of December 31, 2025, current assets were $259 million, including cash, cash equivalents, and restricted cash of $91 million. An additional $3 million of restricted cash was classified as a non-current asset. The Company had senior secured term loan debt, net of discount and issuance costs, of $311 million and a mortgage loan, net of discount and issuance costs, of $19 million.
- Total shares on a fully converted basis to Subordinate Voting Shares were 491,585,556 as of December 31, 2025.
Conference Call and Webcast
The Company will host a conference call and webcast to discuss its financial results on Thursday, March 5, 2026 , at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via w ebcast or by dialing 1-833-470-1428 (US Toll Free) or 1-646-844-6383 (US Local), and providing access code 152399. Archived access to the webcast will be available for one year on Cresco Labs’ investor website, here .
Consolidated Financial Statements
The financial information reported in this press release contains certain preliminary financial results for the three months and year ended December 31, 2025. These financial statements have been prepared in accordance with U.S. GAAP. These preliminary results for the three months and year ended December 31, 2025, are provided prior to completion of all internal reviews and external audit procedures and are therefore subject to adjustment until the filing of the Company's audited consolidated financial statements, which the Company expects to file on SEDAR+ and EDGAR on or about March 5, 2026. The audit of the consolidated financial statements for the year ended December 31, 2025, is currently in process. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the consolidated financial statements it files on SEDAR+ and EDGAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company’s financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company’s filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission, for any purposes, that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company’s audited financial statements for the year ended December 31, 2025, filed on SEDAR+ and EDGAR.
Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the “Non-GAAP Financial Measures” section below for more detailed information.
Non-GAAP Financial Measures
This release reports its financial results in accordance with U.S. GAAP and includes certain non-GAAP financial measures that do not have standardized definitions under U.S. GAAP. The non-GAAP measures include: Earnings before interest, taxes, depreciation, and amortization (“EBITDA”); Adjusted EBITDA; Adjusted EBITDA margin; Adjusted gross profit; Adjusted gross profit margin; Adjusted selling, general, and administrative expenses (“Adjusted SG&A”), Adjusted SG&A margin; and Free Cash Flow are non-GAAP financial measures and do not have standardized definitions under U.S. GAAP. The Company defines these non-GAAP financial measures as follows: EBITDA as net loss (income) before interest, taxes, depreciation, and amortization; Adjusted EBITDA as EBITDA less other (expense) income, net, fair value mark-up for acquired inventory, adjustments for acquisition and non-core costs, impairment and share-based compensation; Adjusted EBITDA Margin as Adjusted EBITDA divided by revenues, net; Adjusted gross profit as gross profit less fair value mark-up for acquired inventory and adjustments for acquisition and non-core costs; Adjusted gross profit margin as Adjusted gross profit divided by revenues, net; Adjusted SG&A as SG&A less adjustments for acquisition and non-core costs; Adjusted SG&A margin as Adjusted SG&A divided by revenues, net; and Free Cash Flow as Net cash provided by operating activities less purchases of property and equipment and proceeds from tenant improvement allowances. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.
About Cresco Labs Inc.
Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook , X or LinkedIn .
Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential,’ or ‘continue,’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2025, expected to be filed on or about March 5, 2026, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
Cresco Labs Inc. | ||||||||||||||||||||
Financial Information and Non-GAAP Reconciliations | ||||||||||||||||||||
(All amounts expressed in thousands of U.S. Dollars) | ||||||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||||||
For the Three Months Ended December 31, 2025, September 30, 2025, and December 31, 2024 | ||||||||||||||||||||
and | ||||||||||||||||||||
Years Ended December 31, 2025 and December 31, 2024 | ||||||||||||||||||||
For the Three Months Ended | For the Year Ended | |||||||||||||||||||
($ in thousands) | December 31, | September 30, | December 31, | December 31, | December 31, | |||||||||||||||
(unaudited) | (unaudited) | (unaudited) | ||||||||||||||||||
Revenues, net | $ | 161,553 | $ | 164,913 | $ | 175,909 | $ | 655,847 | $ | 724,343 | ||||||||||
Cost of goods sold | 78,232 | 85,553 | 91,883 | 331,279 | 359,889 | |||||||||||||||
Gross profit | 83,321 | 79,360 | 84,026 | 324,568 | 364,454 | |||||||||||||||
Gross profit % | 51.6 | % | 48.1 | % | 47.8 | % | 49.5 | % | 50.3 | % | ||||||||||
Operating expenses: | ||||||||||||||||||||
Selling, general, and administrative | 57,014 | 51,640 | 56,030 | 217,863 | 221,269 | |||||||||||||||
Share-based compensation | 3,415 | 1,891 | 3,133 | 9,413 | 11,803 | |||||||||||||||
Depreciation and amortization | 4,966 | 5,636 | 5,457 | 20,178 | 21,770 | |||||||||||||||
Impairment loss | 93,471 | 2,365 | — | 105,101 | 2,320 | |||||||||||||||
Total operating expenses | 158,866 | 61,532 | 64,620 | 352,555 | 257,162 | |||||||||||||||
Income from operations | (75,545 | ) | 17,828 | 19,406 | (27,987 | ) | 107,292 | |||||||||||||
Other (expense) income, net: | ||||||||||||||||||||
Interest expense, net 2 | (14,264 | ) | (14,140 | ) | (13,195 | ) | (56,280 | ) | (54,601 | ) | ||||||||||
Other income (expense) , net 2 | 2,664 | (13,789 | ) | (3,156 | ) | (11,155 | ) | (63,307 | ) | |||||||||||
Total other expense, net | (11,600 | ) | (27,929 | ) | (16,351 | ) | (67,435 | ) | (117,908 | ) | ||||||||||
(Loss) Income before income taxes | (87,145 | ) | (10,101 | ) | 3,055 | (95,422 | ) | (10,616 | ) | |||||||||||
Income tax expense | (1,804 | ) | (11,867 | ) | (2,616 | ) | (44,622 | ) | (49,873 | ) | ||||||||||
Net (loss) income 1 | $ | (88,949 | ) | $ | (21,968 | ) | $ | 439 | $ | (140,044 | ) | $ | (60,489 | ) | ||||||
1 Net (loss) income includes amounts attributable to non-controlling interests. | ||||||||||||||||||||
2 Certain immaterial prior period amounts were reclassified to conform to the current presentation. |
Cresco Labs Inc. | ||||||||||||||||||||
Unaudited Reconciliation of Gross Profit to Adjusted Gross Profit (Non-GAAP) | ||||||||||||||||||||
For the Three Months Ended December 31, 2025, September 30, 2025, and December 31, 2024 | ||||||||||||||||||||
and | ||||||||||||||||||||
Years Ended December 31, 2025 and December 31, 2024 | ||||||||||||||||||||
For the Three Months Ended | For the Year Ended | |||||||||||||||||||
($ in thousands) | December 31, | September 30, | December 31, | December 31, | December 31, | |||||||||||||||
Revenues, net | $ | 161,553 | $ | 164,913 | $ | 175,909 | $ | 655,847 | $ | 724,343 | ||||||||||
Cost of goods sold 1 | 78,232 | 85,553 | 91,883 | 331,279 | 359,889 | |||||||||||||||
Gross profit | $ | 83,321 | $ | 79,360 | $ | 84,026 | $ | 324,568 | $ | 364,454 | ||||||||||
Fair value mark-up for acquired inventory | 28 | — | — | 28 | 123 | |||||||||||||||
Cost of goods sold adjustments for acquisition and other non-core costs | 1,049 | 1,110 | 3,121 | 4,795 | 9,447 | |||||||||||||||
Adjusted gross profit (Non-GAAP) | $ | 84,398 | $ | 80,470 | $ | 87,147 | $ | 329,391 | $ | 374,024 | ||||||||||
Adjusted gross profit % (Non-GAAP) | 52.2 | % | 48.8 | % | 49.5 | % | 50.2 | % | 51.6 | % | ||||||||||
1 Production (cultivation, manufacturing, and processing) costs related to products sold during the period. |
Cresco Labs Inc. | ||||||
Summarized Consolidated Statements of Financial Position | ||||||
As of December 31, 2025 and December 31, 2024 | ||||||
($ in thousands) | December 31, 2025 | December 31, 2024 | ||||
Cash, cash equivalents, and restricted cash (current) | $ | 91,086 | $ | 141,003 | ||
Other current assets | 168,187 | 153,254 | ||||
Property and equipment, net | 327,192 | 344,846 | ||||
Intangible assets, net | 275,342 | 293,994 | ||||
Goodwill | 208,173 | 283,484 | ||||
Other non-current assets | 127,320 | 138,774 | ||||
Total assets | $ | 1,197,300 | $ | 1,355,355 | ||
Total current liabilities | $ | 100,180 | $ | 94,338 | ||
Total non-current liabilities | 844,618 | 872,841 | ||||
Total shareholders’ equity | 252,502 | 388,176 | ||||
Total liabilities and shareholders’ equity | $ | 1,197,300 | $ | 1,355,355 |
Cresco Labs Inc. | ||||||||||||||||||||
Unaudited Reconciliation of SG&A to Adjusted SG&A (Non-GAAP) | ||||||||||||||||||||
For the Three Months Ended December 31, 2025, September 30, 2025, and December 31, 2024 | ||||||||||||||||||||
and Years Ended December 31, 2025 and December 31, 2024 | ||||||||||||||||||||
For the Three Months Ended | For the Year Ended | |||||||||||||||||||
($ in thousands) | December 31, | September 30, | December 31, | December 31, | December 31, | |||||||||||||||
Selling, general, and administrative | $ | 57,014 | $ | 51,640 | $ | 56,030 | $ | 217,863 | $ | 221,269 | ||||||||||
Adjustments for acquisition and other non-core costs | 7,702 | 3,920 | 2,299 | 18,327 | 9,656 | |||||||||||||||
Adjusted SG&A (Non-GAAP) | $ | 49,312 | $ | 47,720 | $ | 53,731 | $ | 199,536 | $ | 211,613 | ||||||||||
Adjusted SG&A % (Non-GAAP) | 30.5 | % | 28.9 | % | 30.5 | % | 30.4 | % | 29.2 | % |
Cresco Labs Inc. | ||||||||||||||||||||
Unaudited Reconciliation of Net Loss to Adjusted EBITDA (Non-GAAP) | ||||||||||||||||||||
For the Three Months Ended December 31, 2025, September 30, 2025, and December 31, 2024 | ||||||||||||||||||||
and | ||||||||||||||||||||
Years Ended December 31, 2025 and December 31, 2024 | ||||||||||||||||||||
For the Three Months Ended | For the Year Ended | |||||||||||||||||||
($ in thousands) | December 31, | September 30, | December 31, | December 31, | December 31, | |||||||||||||||
Net (loss) income 1 | $ | (88,949 | ) | $ | (21,968 | ) | $ | 439 | $ | (140,044 | ) | $ | (60,489 | ) | ||||||
Depreciation and amortization | 10,758 | 12,858 | 13,904 | 48,712 | 59,096 | |||||||||||||||
Interest expense, net 2 | 14,264 | 14,140 | 13,195 | 56,280 | 54,601 | |||||||||||||||
Income tax expense | 1,804 | 11,867 | 2,616 | 44,622 | 49,873 | |||||||||||||||
EBITDA (Non-GAAP) | $ | (62,123 | ) | $ | 16,897 | $ | 30,154 | $ | 9,570 | $ | 103,081 | |||||||||
Other (expense) income, net 2 | (2,664 | ) | 13,789 | 3,156 | 11,155 | 63,307 | ||||||||||||||
Fair value mark-up for acquired inventory | 28 | — | — | 28 | 123 | |||||||||||||||
Adjustments for acquisition and other non-core costs | 8,071 | 4,443 | 4,493 | 20,263 | 16,851 | |||||||||||||||
Impairment loss | 93,471 | 2,365 | — | 105,101 | 2,320 | |||||||||||||||
Share-based compensation | 3,652 | 2,311 | 3,705 | 11,232 | 14,164 | |||||||||||||||
Adjusted EBITDA (Non-GAAP) | $ | 40,435 | $ | 39,805 | $ | 41,508 | $ | 157,349 | $ | 199,846 | ||||||||||
Adjusted EBITDA % (Non-GAAP) | 25.0 | % | 24.1 | % | 23.6 | % | 24.0 | % | 27.6 | % | ||||||||||
1 Net (loss) income includes amounts attributable to non-controlling interests. | ||||||||||||||||||||
2 Certain immaterial prior period amounts were reclassified to conform to the current presentation. |
Cresco Labs Inc. | ||||||||||||||||||||
Summarized Consolidated Statements of Cash Flows | ||||||||||||||||||||
For the Three Months Ended December 31, 2025, September 30, 2025, and December 31, 2024 | ||||||||||||||||||||
and | ||||||||||||||||||||
Years Ended December 31, 2025 and December 31, 2024 | ||||||||||||||||||||
For the Three Months Ended | For the Year Ended | |||||||||||||||||||
($ in thousands) | December 31, | September 30, | December 31, | December 31, | December 31, | |||||||||||||||
(unaudited) | (unaudited) | (unaudited) | ||||||||||||||||||
Net cash provided by operating activities | $ | 27,432 | $ | 6,164 | $ | 29,486 | $ | 72,890 | $ | 132,480 | ||||||||||
Net cash used in investing activities | (13,242 | ) | (6,124 | ) | (3,013 | ) | (40,704 | ) | (25,229 | ) | ||||||||||
Net cash used in financing activities | (1,793 | ) | (71,096 | ) | (42,034 | ) | (82,088 | ) | (71,478 | ) | ||||||||||
Effect of foreign currency exchange rate changes on cash and cash equivalents | (17 | ) | — | 9 | (17 | ) | (39 | ) | ||||||||||||
Net increase (decrease) in cash and cash equivalents | $ | 12,380 | $ | (71,056 | ) | $ | (15,552 | ) | $ | (49,919 | ) | $ | 35,734 | |||||||
Cash and cash equivalents and restricted cash, beginning of period | 81,956 | 153,012 | 159,806 | 144,254 | 108,520 | |||||||||||||||
Cash and cash equivalents and restricted cash, end of period | $ | 94,336 | $ | 81,956 | $ | 144,254 | $ | 94,335 | $ | 144,254 |
Cresco Labs Inc. | ||||||||||||||||||||
Unaudited Reconciliation of Operating Cash Flow to Free Cash Flow (Non-GAAP) | ||||||||||||||||||||
For the Three Months Ended December 31, 2025, September 30, 2025, and December 31, 2024 | ||||||||||||||||||||
and | ||||||||||||||||||||
Years Ended December 31, 2025 and December 31, 2024 | ||||||||||||||||||||
For the Three Months Ended | For the Year Ended | |||||||||||||||||||
($ in thousands) | December 31, | September 30, | December 31, | December 31, | December 31, | |||||||||||||||
Net cash provided by operating activities | $ | 27,432 | $ | 6,164 | $ | 29,486 | $ | 72,890 | $ | 132,480 | ||||||||||
Purchases of property and equipment | (9,016 | ) | (7,180 | ) | (3,204 | ) | (35,138 | ) | (19,492 | ) | ||||||||||
Proceeds from tenant improvement allowances | — | — | 439 | 501 | 1,055 | |||||||||||||||
Free Cash Flow (Non-GAAP) | $ | 18,416 | $ | (1,016 | ) | $ | 26,721 | $ | 38,253 | $ | 114,043 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260305447476/en/
Media
Press@crescolabs.com
Investors
TJ Cole, Cresco Labs
SVP, Corporate Development & Investor Relations
investors@crescolabs.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
FAQ**
Given the significant net loss of $140 million for Cresco Labs Inc. (Sub Voting) CRLBF in 2025, what steps is the company taking to improve profitability in the coming years?
How is Cresco Labs Inc. (Sub Voting) CRLBF planning to manage its $311 million senior secured term loan debt in light of ongoing market challenges?
What specific strategies does Cresco Labs Inc. (Sub Voting) CRLBF have in place to sustain its No. 1 market share position amidst ongoing industry consolidation?
Can you elaborate on the potential impacts of federal reform on Cresco Labs Inc. (Sub Voting) CRLBF’s growth plans and outlook for future revenue generation?
**MWN-AI FAQ is based on asking OpenAI questions about Cresco Labs Inc. (CNQC: CL:CC).
NASDAQ: CL:CC
CL:CC Trading
5.28% G/L:
$5.58 Last:
952,960 Volume:
$5.18 Open:
